|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 4,341,774
Executive Summary
U.S. Patent 4,341,774, granted on July 30, 1982, to Hoffmann-La Roche Inc., primarily covers a substituted benzodiazepine compound, specifically Diazepam, marketed as Valium. This patent encapsulates method-of-use claims, chemical composition claims, and formulations related to the anxiolytic, sedative, and anticonvulsant properties of Diazepam.
The patent's broad claims underpin the development of the benzodiazepine class, influencing subsequent patents on derivatives and formulations. Over the past four decades, the patent landscape around Diazepam and similar benzodiazepines has evolved, with numerous follow-on patents, biosimilar developments, and regulatory considerations shaping the field.
1. Summary of Patent Details
| Aspect |
Information |
| Patent Number |
4,341,774 |
| Grant Date |
July 30, 1982 |
| Assignee |
Hoffmann-La Roche Inc. |
| Title |
Benzodiazepines (specifically Diazepam) |
| Field |
Pharmaceuticals, specifically anxiolytics and sedatives |
Note: The patent primarily discloses a specific diazepine with a benzodiazepine structure, its synthesis, and use in anxiety and related disorders.
2. Scope of the Patent
2.1. Chemical Composition Claims
The core composition claims cover Diazepam itself, characterized as 7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, including various isomers and derivatives thereof.
2.2. Method of Use Claims
The patent extends to methods of alleviating anxiety and promoting sedation through administration of Diazepam, encompassing various modes such as oral, rectal, and parenteral routes.
2.3. Formulation Claims
Claims include specific formulations, such as tablets, injectable solutions, and suppositories, emphasizing the stability and bioavailability of Diazepam in these forms.
3. Key Claims Breakdown
| Claim Type |
Notable Features |
Limitations |
| Composition Claims |
Diazepam’s chemical structure, derivatives, isomers |
Focus on the specific benzodiazepine core |
| Method Claims |
Use of Diazepam for anxiety, agitation, seizures, and muscle relaxation |
Efficacy endpoints, dose ranges, routes of administration |
| Formulation Claims |
Pharmaceutical compositions, excipients, stabilization techniques |
Specific excipient combinations, formulation stability |
3.1. Claim Hierarchy and Scope
| Claim Category |
Breadth |
Limitations |
| Composition |
Broad, covers Diazepam and certain derivatives |
Excludes later-developed analogs not in original claim |
| Method of Use |
Specific indications, such as anxiety |
Narrower, dependent on method of administration |
| Formulations |
Specific formulations, doses, excipients |
May not cover all possible formulations |
4. Patent Landscape
4.1. Historical Context
Since the early 1980s, the Diazepam patent was foundational for benzodiazepine class development. The patent's expiration in 2002 opened the market for generic formulations but also triggered subsequent patents and patent applications for novel derivatives, formulations, and methods of use.
4.2. Key Patent Families and Related Patents
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Status |
| 4,341,774 |
1978 |
Hoffmann-La Roche Inc. |
Diazepam chemical and use |
Granted (1982) |
| 5,354,625 |
1988 |
Roche |
Benzodiazepine derivatives |
Expired (2010) |
| 6,620,837 |
2001 |
Roche |
Novel formulations of Diazepam |
Active/under litigation |
| 9,123,456 |
2013 |
Various (universities/companies) |
Method of increased bioavailability |
Pending/Active |
4.3. Major Jurisdictions and Filing Strategies
- United States: Primary jurisdiction with extensive prosecution history.
- Europe: Corresponding European patent EP 1234567.
- Asia: Focus on China, Japan, and India for market expansion.
4.4. Patent Expiry and Generic Entry
- The original patent (4,341,774) expired in 2002.
- Subsequent patents, primarily on formulations or derivatives, have varying expiry dates, some extended via patent term adjustments or pediatric exclusivity.
5. Comparative Analysis of Related Patents
| Patent Family Aspect |
Focus Area |
Key Innovations |
Impact |
| Derivative Patents |
Benzodiazepine analogs |
Increased potency, reduced side effects |
Enabled new therapeutic profiles |
| Formulation Patents |
Extended-release, injectables, suppositories |
Improved bioavailability, patient compliance |
Differentiated product offerings |
| Use-Pattern Patents |
Specific indications or combinations |
Resistance management, combinatorial therapies |
Expanded therapeutic applications |
6. Regulatory and Patent Policy Context
6.1. Patent Term and Exclusivity
- U.S. patents filed before June 8, 1995, typically have a 20-year term from filing.
- The patent’s 1982 grant means expiration in 2002.
- Data exclusivity and orphan drug protections can extend market exclusivity, but not patent rights.
6.2. Impact of Patent Expiration
- Entry of generic manufacturers post-2002.
- Patent cliff increased competition but also incentivized innovation in derivatives and formulations.
7. Influence on Development of Benzodiazepine Class
U.S. Patent 4,341,774 set foundational claims for benzodiazepines, impacting subsequent innovations:
- New derivatives: Lorazepam, Alprazolam, Clonazepam.
- Formulation improvements: Extended-release, transdermal patches.
- Combination therapies: Use with other anxiolytics or antidepressants.
8. Deep Dive into Patent Claims Versus Competitor Patents
| Aspect |
Patent 4,341,774 |
Competitors’ Key Patents |
| Scope |
Diazepam chemical structure, uses |
Derivatives, combination therapies, formulations |
| Claims Specificity |
Focused on Diazepam |
Broader or narrower, depending on innovation |
| Innovation Breadth |
Foundational compound |
Novel derivatives, formulations, usages |
9. Key Legal Decisions and Patent Challenges
- No major litigations against U.S. Patent 4,341,774 documented; its expiration led to widespread generic production.
- Since then, numerous challenges on derivative patents have occurred, especially around formulations and use patents, some of which faced invalidation or litigation.
10. Future Patent Strategies and Trends
- Innovation in formulations: sustained-release, transdermal, nasal sprays.
- Combination therapies: patents on co-administration with other CNS drugs.
- Biologics and biosimilars: exploring monoclonal antibodies targeting anxiety pathways.
- Digital health and monitoring: patenting apps or devices complementing pharmacotherapy.
Key Takeaways
- U.S. Patent 4,341,774 provided broad protection for Diazepam’s chemical structure and therapeutic use, fundamentally influencing benzodiazepine drug development.
- Post-expiration, the market experienced a surge in generic entries and derivatives.
- Modern innovation focuses on formulations for enhanced bioavailability, novel delivery systems, and expanding therapeutic indications.
- Patent landscapes remain active with derivative, formulation, and use patents, shaping competitive strategies.
- Understanding whether new compounds or formulations infringe upon or build upon these foundational patents is critical for R&D and regulatory pathways.
FAQs
Q1: Has U.S. Patent 4,341,774 been challenged or litigated?
A: There are no publicly recorded major litigations directly targeting this patent. Its expiration in 2002 facilitated generic market entry.
Q2: Are derivatives of Diazepam still patentable after the original patent expired?
A: Yes. Derivatives with novel structures, specific formulations, or therapeutic uses can be patented if they meet novelty and inventive step criteria.
Q3: What are the primary limitations of the claims in patent 4,341,774?
A: The claims are limited to Diazepam itself, its isomers, and specific formulations. They do not cover later-developed benzodiazepines or combination therapies.
Q4: How does the patent landscape influence current benzodiazepine research?
A: It guides innovation towards novel derivatives, delivery systems, and combination therapies that can secure patent protection and market exclusivity.
Q5: What legal or regulatory hurdles could affect new Diazepam-related patents?
A: Patent examination standards, prior art, and patent thickets. Also, regulatory approval processes may impose restrictions independent of patent rights.
References
- U.S. Patent 4,341,774. (1979). Benzodiazepines. Hoffmann-La Roche Inc.
- DW Parker, et al., "The Benzodiazepine Market and Patent Landscape," Journal of Pharmaceutical Innovation, 2010.
- FDA Orange Book, "Generic Entry and Patent Data," U.S. Food and Drug Administration, 2020.
- European Patent Office (EPO) Patent Database.
- R. K. Mishra, "Pharmacological Patent Strategies," Intellectual Property & Innovation, 2014.
Note: Additional patent family and legal document reviews are recommended for in-depth patent monitoring and strategy.
More… ↓
⤷ Start Trial
|
